Literature DB >> 21702020

Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.

I Marie1, P Y Hatron, S Dominique, P Cherin, L Mouthon, J-F Menard.   

Abstract

OBJECTIVE: This study was undertaken to assess the characteristics and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) and to determine variables predictive of ILD deterioration in PM/DM.
METHODS: Among 348 consecutive patients with PM/DM, 107 patients with ILD were identified by medical records search in 4 medical centers. All patients underwent pulmonary function tests (PFTs) and pulmonary high-resolution computed tomography (HRCT) scan.
RESULTS: ILD onset preceded PM/DM clinical manifestations in 20 patients, was identified concurrently with PM/DM in 69 patients, and occurred after PM/DM onset in 18 patients. Patients with ILD could be divided into 3 groups according to their presenting lung manifestations: patients with acute lung disease (n = 20), patients with progressive-course lung signs (n = 55), and asymptomatic patients with abnormalities consistent with ILD evident on PFTs and HRCT scan (n = 32). We observed that 32.7% of the patients had resolution of pulmonary disorders, whereas 15.9% experienced ILD deterioration. Factors that predicted a poor ILD prognosis were older age, symptomatic ILD, lower values of vital capacity and diffusing capacity for carbon monoxide, a pattern of usual interstitial pneumonia on HRCT scan and lung biopsy, and steroid-refractory ILD. The mortality rate was higher in patients with ILD deterioration than in those without ILD deterioration (47.1% versus 3.3%).
CONCLUSION: Our findings indicate that ILD results in high morbidity in PM/DM. Our findings also suggest that more aggressive therapy may be required in PM/DM patients presenting with factors predictive of poor ILD outcome.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2011        PMID: 21702020     DOI: 10.1002/art.30513

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  70 in total

Review 1.  Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review.

Authors:  Yongpeng Ge; Qinglin Peng; Sigong Zhang; Hang Zhou; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2014-11-01       Impact factor: 2.980

2.  Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Authors:  Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff
Journal:  Chest       Date:  2019-06-22       Impact factor: 9.410

Review 3.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

Review 4.  Idiopathic inflammatory myopathies-a review.

Authors:  Jonathan Jones; Robert Wortmann
Journal:  Clin Rheumatol       Date:  2015-02-14       Impact factor: 2.980

Review 5.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

6.  Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.

Authors:  Yue Zhong; Wenjuan Bai; Qibing Xie; Jianhong Sun; Hong Tang; Li Rao
Journal:  Int J Cardiovasc Imaging       Date:  2017-11-22       Impact factor: 2.357

7.  Inflammatory myopathies: One-center experience.

Authors:  Metin Işık; Şule Bilgen; İsmail Doğan; Levent Kılıç
Journal:  Eur J Rheumatol       Date:  2014-09-01

8.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

9.  Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).

Authors:  Jorge Rojas-Serrano; Denisse Herrera-Bringas; Mayra Mejía; Hermes Rivero; Heidegger Mateos-Toledo; José E Figueroa
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

10.  Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.

Authors:  Dong Jin Go; Jin Kyun Park; Eun Ha Kang; Hyun Mi Kwon; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Rheumatol Int       Date:  2015-07-30       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.